Ac t i o n | 18 Aug 2026 08:46:54 ET │ 12 pages Amylyx Pharmaceuticals, Inc. (AMLX.O) Avexitide's phase 3 comes in with LUCIDITY; Raising TP to $32 CITI'S TAKE LUCIDITY delivered a strong phase 3 topline (preview here), with avexitide (GLP-1 antagonist) for post-bariatric hypoglycemia (PBH) reducing composite Level 2/3 hypoglycemic events by 55% vs. placebo (p=0.000003) and meeting all secondary endpoints. The magnitude replicated PREVENT's placebo-adjusted effect, exceeded the 35% treatment effect used to ...